MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Excellent Non-motor Responses after Bilateral Subthalamic Deep Brain Stimulation in Parkinson’s Disease Patient with SNCA Duplication

    J. Youn, J.W. Cho, J.-I. Lee (Seoul, Republic of Korea)

    Objective: We report a case of Parkinson's disease patient with SNCA duplication, who showed excellent response in both motor and non-motor symptoms after bilateral subthalamic stimulation. Background:…
  • 2017 International Congress

    Asymptomatic and transitory postoperative hypodense lesion around deep brain stimulation electrode

    M. Sousa, F. Moreira, N. Canário, O. Brito, R. Pereira, M. Rito, C. Januário (Coimbra, Portugal)

    Objective: To report the case of a patient that developed a post-operative asymptomatic, transitory, non-infection hypodense lesion around DBS lead, literature review and discussion of…
  • 2017 International Congress

    Transcranial sonography in the prognosis of drug-induced parkinsonism

    Y.-S. Oh, D.-Y. Kwon (Seoul, Republic of Korea)

    Objective: We investigated the substantia nigra (SN) echogenicity in drug-induced parkinsonism (DIP), Parkinson's disease (PD), and healthy controls. A subgroup analysis of DIP by clinical…
  • 2017 International Congress

    Effects of the administration of levodopa on postural control under visual tasks

    C. Bonnet, A. Delval, L. Defebvre (Lille, France)

    Objective: We tested if the administration of levodopa leads the patients with Parkinson’s disease to sway significantly more than the controls, especially under challenging visual…
  • 2017 International Congress

    Effect of Deutetrabenazine on QTcF Interval in the AIM-TD Study: a 12-Week, Phase III, Randomized, Double-Blind, Placebo-Controlled Study

    K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, H. Fernandez (Washington, DC, USA)

    Objective: To evaluate the effect of deutetrabenazine (DTB) on QT interval prolongation in patients with tardive dyskinesia (TD) in the AIM-TD study. Background: TD is…
  • 2017 International Congress

    Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease

    K. Steece-Collier, T. Collier, J. Stancati, C. Kemp, B. Daley, C. Sortwell (Grand Rapids, MI, USA)

    Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…
  • 2017 International Congress

    Low Incidence of Extrapyramidal Symptoms in Subjects with Tardive Dyskinesia Receiving Long-Term Valbenazine (NBI-98854) Treatment

    S. Lessig, R. Kurlan, S. Factor, J. Burke, C. Wright, R. Jimenez, G. Liang (La Jolla, CA, USA)

    Objective: To assess the emergence of extrapyramidal symptoms (EPS) such as akathisia and parkinsonism in adults with a diagnosis of schizophrenia/schizoaffective disorder or mood disorder…
  • 2017 International Congress

    Prevalence of Parkinson’s disease and Drug-induced Parkinsonism from National Health Insurance Service Claims Data (NHISCD)

    H.-I. MA, S. Jang, J.-s. Kim, S.J. Chung, J.S. Baik, Y.J. Kim (Anyang, Republic of Korea)

    Objective: To evaluate the prevalence and characteristics of of drug induced parkinsonism Background: Drug induced parkinsonism (DIP) is a clinically important disease because it can…
  • 2017 International Congress

    Drug-induced movement disorders: not a typical problem

    A. Vives-Rodriguez, A. Patel (New Haven, CT, USA)

    Objective: To characterize patients with neuroleptic drug-induced movement disorders (DIMD) referred to a single academic center Movement Disorders clinic, their causative medications and the indications…
  • 2017 International Congress

    Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study

    K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, H. Fernandez (Washington, DC, USA)

    Objective: To evaluate the long-term safety/tolerability of deutetrabenazine (DTB) in patients with tardive dyskinesia (TD). Week 54 open-label results are reported in this interim analysis.…
  • « Previous Page
  • 1
  • …
  • 1619
  • 1620
  • 1621
  • 1622
  • 1623
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley